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Abstract
BACKGROUND: Aim ot the study was to assess the role of 
planar lymphoscintigraphy and fusion imaging of SPECT/CT 
in sentinel lymph node (SLN) detection in patients with vari-
ous types of tumours and to estimate some factors influencing 
detection success — age and body mass index.
MATERIAL AND METHODS: Planar scintigraphy and hybrid 
modality SPECT/CT were performed in 550 consecutive patients 
(mean age 58.1 ± 13.1 years): 69 pts with gynaecological 
tumours (37 pts with cervical cancer, 25 pts with endometrial 
cancer, 7 pts with vulvar carcinoma; mean age 54.4 ± 13.2 
years), 161 consecutive patients with melanomas (mean age 
57.1 ± 14.8 years), and 320 consecutive women with breast 
cancer (mean age 59.4 ± 12.0 years). The radiopharmaceuti-
cal was injected around the tumour (gynaecologic and breast 
cancers, melanomas), subareolarly (in some breast cancers), or 
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around the scar (in melanomas after their removal). Planar and 
SPECT/CT images were interpreted separately by two nuclear 
medicine physicians. 
RESULTS: Planar scintigraphy did not show SLN in 77 patients 
(14.0%): in 8 pts with gynaecologic tumours, in 23 pts with mela-
nomas and in 46 pts with breast cancer. SPECT/CT was negative 
in 49 patients (8.9%): in 4 pts with gynaecologic tumours, in 12 
pts with melanomas and in 33 pts with breast cancer. In 199 
(36.2%) patients the number of SLNs captured on SPECT/CT 
was higher than on planar imaging. 35 foci of uptake (3.1% from 
totally visible 1134 foci on planar images) interpreted on planar 
images as hot LNs were found to be false positive non-nodal 
sites of uptake when further assessed on SPECT/CT. SPECT/CT 
showed the exact anatomical location of all visualized sentinel 
nodes. Influence of the age and BMI: The group of patients with 
higher number of detected SLN on SPECT/CT than on planar 
scintigraphy had lower average age than the group of patients 
with the same number of detected SLN on SPECT/CT and on 
planar scintigraphy, the difference was statistically significant 
(P=0.008). BMI did not differ between the two groups.
CONCLUSION: In some patients with gynaecologic and breast 
cancers and melanomas, SPECT/CT improves detection of 
sentinel lymph nodes. It can image nodes not visible on planar 
scintigrams, exclude false positive uptake and exactly local-
ize axillary, inguinal, pelvic and paraaortic SLNs. It improves 
anatomical localization of SLNs. We have found the influence 
of the age on the difference in the number of SLNs detected by 
the fusion of SPECT/CT and planar lymphoscintigraphy. On the 
other hand, this difference was not influenced by BMI. 
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Background
Sentinel lymph node (SLN) has been incorporated in the routine 
management of various types of solid tumour [1–3]. Lymph node 
status in malignant tumours remains a most important prognostic 
factor for recurrence and survival and a major decision criterion for 
adjuvant therapy [4, 5]. Sentinel lymph node biopsy is the most 
accurate and the only reliable method for nodal staging which can 
diagnose microscopic tumour spread to the regional lymph nodes. 
Lymphoscintigraphy visualizes where lymph from the primary tu-
mour site travels and, therefore, is an essential element of lymphatic 
mapping [6, 7]. The use of lymphatic mapping, SLN identification 
and biopsy in patients with some types of malignant tumours may 
help reduce the morbidity of surgery. Minimal invasive SLN biopsy 
can replace lymphadenectomy for staging. Planar lymphoscinti-
graphic imaging is an important element in lymphatic mapping, 
but interpretation of planar lymphoscintigrams is hindered by the 
absence of anatomical landmarks in the scintigraphic image [8]. 
An essential step in the procedure for SLN biopsy is to locate the 
first-echelon node of draining basin. In some patients, however, the 
lymphoscintigram shows a drainage pattern that is difficult to inter-
pret and in a small minority no sentinel node is depicted at all [9].
Sentinel lymph node biopsy has an established role in malignant 
melanoma and breast cancer [3, 10]. A group of patients who might 
benefit from a SLN biopsy are those with cancer of the uterine cervix 
and other gynaecological malignancies.
In our study we compare hybrid SPECT/CT and planar lym-
phoscintigraphy in patients with various tumours and explore the 
value of SPECT/CT — mainly for detection of additional SLNs, the 
exact anatomical localization of SLNs, and differentiation of skin 
contamination. We estimated some factors influencing detection 
success of SLN — age and BMI.
Materials and methods
Patient population
Planar and hybrid SPECT/low-dose CT lymphoscintigraphy 
were performed in 550 consecutive patients (mean age 58.1 ± 13.1 
years, BMI 27.8 ± 5.1): 69 pts with gynaecological tumours (37 with 
cervical cancer, 25 pts with endometrial cancer, 7 pts with vulvar 
carcinoma; mean age 54.4 ± 13.2 years, BMI 27.5 ± 5.0), 161 con-
secutive patients with melanomas (87 men, 74 women; mean age 
57.1 ± 14.8 years, BMI 28.4 ± 5.1), and 320 consecutive women 
with breast cancer (mean age 59.4 ± 12.0 years, BMI 27.6 ± 5.1) 
with no clinical evidence of lymph node metastases (N0) and no 
remote metastases (M0). 
Lymphoscintigraphic method 
In patients with  gynaecologic tumours (GROUP A), we per-
formed preoperative lymphoscintigraphy utilizing 99mTc-colloid, 
activity 40 MBq, on the operation day (one-day protocol). Gy-
naecologists made 4 injections of colloid around the tumour. 
Scintigraphy followed 25–60 minutes after injection. In melanoma 
patients (GROUP B) on the day of surgery (one day protocol), 
an activity of 100 MBq 99mTc labelled colloid divided in four equal 
aliquots of 0.5 ml was injected by nuclear medicine physician in 
four intradermal injections around the tumour (79 pts) or around 
the scar (82 pts) after excision of the melanoma. In breast cancer 
patients (GROUP C) on the day prior to surgery (2 day protocol 
in 273 patients) or on the day of surgery (one day protocol in 47 
women) an activity of 120 MBq of 99mTc labelled colloid divided in 
four or five equal aliquots of 0.5 ml was injected by nuclear medi-
cine physician. Women with palpable mass were injected in four 
peritumoral sites and one subdermal injection above the tumour 
(273 pts). Patients with nonpalpable tumour were injected in four 
subareolar sites (47 pts). We have used following 99mTc-colloids: 
Nanocis (size of colloid particles 100 nm — 68 pts in all groups), 
Nanocoll (size of colloid particles to 80 nm — 379 pts), SentiScint 
(size of particles to 200 nm — 5 pts), NanoAlbumon (size of parti-
cles to 80 nm — 98 pts). The choice of radiopharmaceuticals (Rf) 
was totally random. The type of Rf was not important because we 
have compared planar scintigraphy and SPECT/CT performed with 
the same Rf in individual patient. 
We previously reported the success of SLNs detection by 
means of various Rfs [3, 11–13] and this is not the aim of our 
present study.
In melanoma patients, the dynamic scintigraphy (parameters: 
matrix 128 × 128, 30 frames, 20 s per frame) was done. In all 
types of tumours, the planar scintigraphy (in melanoma patients pla-
nar scintigraphy was done immediately after dynamic scintigraphy) 
and SPECT/CT lymphoscintigraphy were performed using a hybrid 
system composed of a dual-head gamma camera with a low-dose 
CT installed in a gantry (Symbia T2 Siemens).
Planar lymphoscintigraphy was carried out in the anterior, 
posterior and lateral projections focusing on the area of interest. 
Acquisition time was 10 minutes. If SLN was displayed, to facilitate 
the surgical resection a reference mark was placed on the skin 
with the help of the 57Co mark, corresponding to the position of 
the SLN visualized by lymphoscintigraphy. SPECT/CT images were 
acquired immediately after planar images. The SPECT/CT system 
(Symbia T2; Siemens, Erlangen, Germany) consisted of a du-
al-head variable-angle gamma camera equipped with low-energy 
high-resolution collimators and a two-slice spiral CT scanner opti-
mized for rapid rotation. SPECT acquisition (matrix 128 × 128, 60 
frames at 25 s per view) was performed using steps of 60. CT scan 
was a low-dose, noncontrast study (130 kV, 17 mAs, B60s kernel), 
5 mm slices were created. The iterative reconstruction (OSEM 3D) 
was used for generating SPECT slices. Both SPECT images and 
CT axial slices were fused using an Esoft 2000 application package 
(Siemens, Erlangen, Germany). Hybrid SPECT/CT images were 
viewed using two-dimensional orthogonal re-slicing in axial, sagit-
tal and coronal orientation. Maximum intensity projections with 
a three-dimensional display were generated to localize SLNs in 
relation to anatomical structures. 
Scintigraphic interpretation
Sentinel lymph node localization was interpreted separately 
on planar and SPECT/CT images. Image analysis was performed 
prospectively by two experienced nuclear medicine physicians in 
consensus reading. All images were analysed in two steps: 1. 
analysis of planar images; 2. analysis of coregistered SPECT/CT 
images. The location of SLNs was categorized as axillar, inguinal, 
pelvic, paraaortic and in other lymphatic basins.
In the analysis of the results, fused SPECT/CT images data 
were concluded to be clinically relevant if they identified SLNs which 
were missed on planar images, if they excluded SLN suspected on 
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planar images, or if they localized SLNs in additional or different 
basins than those suggested by planar images.
Statistical test 
Student’s paired t-test was used for comparing numbers of 
nodes found by both techniques; F-test, Student’s t-test and Fish-
er’s exact test were utilized for age and BMI characteristics com-
parisons. P values < 0.05 were considered significant. 
Surgery
On the basis of the scintigraphic findings on both planar and 
SPECT/CT images the surgeon or gynaecologist is guided during 
surgery. An intraoperative hand-held probe (NEO 2000, Neoprobe 
Corporation Dublin, Ohio, USA; detector: crystal of Cadmium Zinc 
Telluride; 12 mm collimated angulated probe) has been used in all 
patients before incision to identify the site with the highest counts of 
lymph nodes in the lymphatic basin. In some patients a patent blue 
dye (BLEU PATENTÉ V 2.5%, Guebert, France) has been injected 
similarly to the earlier colloid injection. 
The surgeon removed all detected SLNs excluding parasternal 
(in intramammary chain — IMC) nodes which are not routinely 
harvested. If some SLNs in patients with breast cancer were meta-
static, the axillary dissection was subsequently (in the same day 
or later) performed. 
Results
On SPECT/CT images, hot nodes were detected in 501 of 
the 550 (91.1%) patients, with a mean of 2.9 ± 2.9 (range 1–11) 
nodes per patient. SPECT/CT showed the exact anatomical loca-
tion of all visualized SLNs. There was a failure to detect SLNs in 
the remaining 49 (8.9%) patients. Planar images identified SLNs in 
473 (86.0%) patients, with a mean of 2.4 ± 1.7 nodes (range 1–12) 
per patient. In the remaining 77 (14.0%) patients no SLNs were 
detected on planar images.
343 lymph nodes in 199 (36.2%) patients were missed on 
planar images, but identified on SPECT/CT. However, 35 (3.1%) 
foci of uptake in 29 patients interpreted on planar images as hot 
LNs were found to be false positive non-nodal sites of uptake when 
further assessed on SPECT/CT. In 31 (5.6%) patients, who had 
planar imaging negative, SPECT/CT visualized lymphatic drainage.
In GROUP A (pts with gynaecologic tumours), planar lym-
phoscintigraphy alone visualized SLN in 61 patients as compared 
to SPECT/CT imaging that identified SLN in 65 patients. The number 
of SLNs captured on SPECT/CT was higher than on planar imaging 
in 38 patients (55.1% of all patients of the GROUP A).
In GROUP B (pts with melanoma), the SLN detection rate 
by SPECT-CT lymphoscintigraphy was 92.5% (in 149 patients), 
by planar imaging 85.7% (in 138 patients), respectively. In 12 
patients (7.5%) SPECT-CT failed to detect hot SLNs. In 12 pa-
tients (7.5%), SLNs were detected only by SPECT-CT and there 
was no patient with SLN detected only by planar images. 
The overall SLN detection rate on SPECT-CT imaging in GROUP 
C (pts with breast cancer) was 89.7% (in 287 pts), and 85.5% (in 
274 pts) by planar scintigraphy. In 33 patients (10.3%) SPECT-CT 
imaging failed to detect hot SLNs. In 15 (4.7%) patients, SLNs were 
detected only on SPECT/CT images.
We found the number of lymph nodes detected on SPECT-CT 
significantly higher than on planar scintigraphy (P < 0.001) both in 
all 550 patients and in each of three groups (A, B and C). 
The age and BMI influencing detection rate by planar scin-
tigraphy and fusion of SPECT/CT: 
The group of patients with higher number of detected SLN on 
SPECT/CT than on planar scintigraphy (199 pts) had lower average 
age (56.4 ± 13.8 years) than the group of patients (351 pts) with 
the same number of detected SLN on SPECT/CT and on planar 
scintigraphy (59.2 ± 12.6 years), the difference was statistically sig-
nificant (P = 0.008). BMI did not differ in these two groups (average 
BMI in the group of patients with higher number of detected SLN 
on SPECT/CT than on planar scintigraphy was 27.7±5.1; average 
BMI in the group of patients with the same number of detected SLN 
on SPECT/CT and on planar scintigraphy was 27.9 ± 5.1). The 
difference was not statistically significant (P = 0.370).
Figures 1, 2, 3, 4, and 5 are the examples of planar scinti-
grams and fusion of SPEC/CT in 70 years old and obese man 
which illustrate the asset of SPECT/CT in older and obese patient. 
Discussion
Sentinel lymph node was defined as the first lymph node drain-
ing the primary tumour, i.e. the first lymph node that is at risk for 
metastatic cells [14]. The histological status of the SLN has been 
found to be an indicator representative of the whole lymph node 
basin. It has turned out to be the strongest predictor for tumour 
recurrence and survival [15].
Lymphatic mapping has been applied extensively in breast 
cancer and melanoma patients [6, 16, 17]. Amongst gynaecologi-
cal cancers, the SLN concept has been most accepted for vulvar 
cancers [18, 19]. A number of researchers have studied SLN detec-
tion in vulvar, endometrial and cervical cancer patients [19, 20–24]. 
The most important prognostic factor in melanomas, breast 
cancers and gynaecologic tumours is the state of the lymph 
nodes [13, 25, 26]. There is not suitable pre-surgery examination 
procedure for detection of affected lymph nodes. The most impor-
tant benefits of the SLN procedure are avoidance of over treatment 
and prevention of morbidity [27, 28, 29, 30]. 
The use of lymphatic mapping and SLN identification may help 
reduce the morbidity of surgery without compromising the identifica-
tion of higher-risk patients who require adjuvant treatment. The SLN 
protocol of enhanced pathologic evaluation of removed nodes may 
also provide a much more detailed evaluation of these nodes and 
Table 1. Numbers of patients with detected lymph nodes
Group A Group B Group C Total
Planar 61 138 274 473
SPECT/CT 65 149 287 501
Table 2. Influence of the age and BMI on SLN detection on 
SPECT/CT and planar scintigraphy 
In all groups Number  
of patients
Average  
age yrs
Average  
BMI
SPECT/CT > planar 199 56.4 ± 13.8 27.7 ± 5.1
SPECT/CT = planar 351 59.2 ± 12.6 27.9 ± 5.1
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Figure 1. 70-year-old man (height 182 cm, weight 110 kg, BMI 33.2) with melanoma on his back in the region of left scapula. In the planar image in 
anterior, posterior and lateral projections three or four deposits on the left side are observed with no possibility of the exact localization of the SLNs
Figure 2. The same patient as in the Figure 1. Fusion of SPECT and CT. Exact localization of SLN in the left axilla
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the potential for identifying micrometastasis that may have been 
missed with traditional pathologic evaluation [31]. 
Accurate visualization of the SLN is required for the best results. 
For example, in gynaecological tumours, the conventional lym-
phoscintigraphy provides planar images with views in only anterior 
or lateral projection and poor spatial information on the location of 
pelvic SLN. In melanomas, lymphoscintigraphy has been found to 
accurately predict the number of nodes in only 81% of the basins, 
overlooking nodes that were superimposed and could not be 
separated from other nodes or from the injection site or lymphatic 
channels and nodes that were beyond the resolution of the planar 
images [32]. The better anatomic definition and improved resolution 
that characterize SPECT images may overcome the above limita-
tions of planar images. Localization of hot lymph nodes on SPECT 
images without anatomic landmarks is not possible. 
A decade ago, hybrid imaging combining single-photon emis-
sion tomography (SPECT) with computed tomography (CT) was in-
troduced for simultaneously acquiring functional and morphological 
information [33]. SPECT/CT was introduced in lymphatic mapping 
with the goal to show more SLNs and to show them more clearly, 
than is possible with planar lymphoscintigraphy, in order to improve 
nodal staging [34]. Hybrid SPECT/CT camera fuses tomographic 
lymphoscintigrams (physiological information) with anatomical data 
from CT [35, 36]. In comparison with traditional single-modality 
Figure 3. The same patient as in the figure 1 and 2. Fusion of SPECT and CT. Exact localization of the second SLN in the left axilla
Figure 4. The same patient as in the Figure 1, 2 and 3. Fusion of SPECT and CT. Exact localization of subcutaneous SLN lateral to left axilla
Nuclear Medicine Review 2013, Vol. 16, No. 1
www.nmr.viamedica.pl22
Original
imaging approaches, the dual-modality systems offer unique ca-
pabilities in combining data from two imaging modalities in way 
that simplifies, yet facilitates, image correlation with the goal of 
revealing useful diagnostic information that is not easily extracted 
when the imaging studies are performed independently [37]. Hybrid 
SPECT/CT provides better contrast and resolution than planar im-
aging with possibility to correct an attenuation and scatter [38, 39]. 
SPECT/CT images provide the topographic landmarks that may 
further facilitate surgical exploration [36] with improvement of surgi-
cal SLNs detection. If only used to correct the radionuclide image 
for photon attenuation, the CT data can be acquired with a consid-
erably lower statistical quality and coarser spatial resolution than 
required for diagnostic-quality imaging and therefore can deliver 
a significantly lower radiation dose than that for a diagnostic CT 
study [37]. Low radiation dose is added to the scintigraphic mapping 
by the low-dose CT, ranging from 1.3 mGy at the centre to 5 mGy at 
the surface of the body [36, 40]. According to low-dose scanning 
protocol we evaluated the radiation exposure from spiral CT to about 
1.5 millisieverts (mSv). Planar nuclear medicine image fusion with CT 
topograms has been proven feasible and offers a clinically suitable 
compromise between improved anatomic details and minimally 
increased radiation dose [8]. Hybrid system allows transmission 
(low-dose CT) and emission (SPECT) scans to be performed without 
changing the patient´s position, thereby allowing for automatic and 
correct record of images obtained with two modalities. 
By visualizing SLN location and neighbouring structures by 
SPECT/CT information, less invasive treatment and thus a reduction 
of operative time, blood loss, and morbidity is likely to occur [33]. 
SPECT/CT has also been reported to reduce the false-positive inter-
pretation of radiotracer accumulation in the event of contamination 
or radiotracer in lymphatic vessels [41]. One of the limitations of 
planar imaging in the detection of SLN is its inability to distinguish 
nodes that are superimposed [42]. A node close to the injection 
site can also be masked as the result of strong activity from the 
injection site (the „shine effect“) [43]. 
The use of SPECT/CT has been described in SLN lymphad-
enectomy for breast cancer, head and neck cancers, melanoma, 
prostate and bladder cancers, vulvar, cervical and endometrial can-
cers — the value of SPECT/CT for SLN identification and localization 
has been described in several reports [6, 31, 33, 44–49]. In special 
instances, SPECT/CT imaging allows for improved detectability and 
interpretation of lymphatic drainage. Contamination, nodes close 
to the injection site, and overweight patients are three noted in-
stances in which SLN identification and localization are better with 
SPECT/CT than with standard planar methods.
The better resolution of SPECT itself, the improved quality of 
attenuation-corrected SPECT images and the improved anatomi-
cal localization of nodes offered by the three-dimensional data of 
the SPECT reconstructed planes as well as the anatomical land-
marks on CT may have contributed to the better nodal identification 
by SPECT/CT found in the study of Leman et al. [50].
Nonvisualization of SLNs is higher in overweight patients with 
breast cancer [51]. Lerman et al. [51] stated that the rate of 
false-negative planar imaging results for 122 overweight and obese 
patients was 28%, higher than that for the general study popula-
tion. The rate of false-negative SPECT/CT results for these 122 
patients was also higher than that for the general study population, 
11%; however, the latter modality identified hot nodes in 18 addi-
tional patients (53%) and had a statistically higher rate of detection 
of SLNs in overweight patients. The addition of SPECT/CT to the ac-
quisition protocol for lymphoscintigraphy in overweight and obese 
patients with breast cancer improves the identification of SLNs and 
avoids false-positive interpretations of sites of nonnodal uptake. 
Before the introduction of SPECT/CT, various methods were 
described to improve the visualization rate of sentinel nodes on 
planar images. Alterations in the colloid particle concentration, 
in the amount of radiotracer and in the time of imaging (early 
versus delayed), a second injection of the radiopharmaceutical, 
and post-injection massage have all been advocated to enhance 
the number of visualized SLNs [52–55]. The combination of all 
Figure 5. The same patient as in the Figure 1, 2, 3 and 4. Fusion of SPECT and CT. Exact localization of SLN on the left side of the nape
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these improvements in the technique has led to a high sensitivity 
of lymphoscintigraphy. Some authors have stated that SPECT/CT, 
therefore, should only be performed in selected patients, i.e. those 
with an unusual lymphatic drainage pattern, with planar images that 
are difficult to interpret or with no visualization on planar images. In 
these patients, SPECT/CT appears to have additional value [56]. 
Moreover, SPECT/CT provides an anatomical overview in two- and 
three-dimensional perspectives creating a surgical road-map that 
cannot be provided by planar images or intraoperative lymphatic 
mapping techniques. The present study confirms the additional 
value of SPECT/CT in the anatomical localization of SLNs and 
underlines its relevance for the surgical approach. SPECT/CT in 
our opinion, therefore, facilitates surgical exploration in difficult 
cases and may improve staging. Other investigators have also 
concluded that additional SPECT/CT after planar lymphoscintig-
raphy resulted in an improved anatomical localization of SLNs. 
Especially SLNs outside the axilla and nodes close to the injection 
site were easier to identify using SPECT/CT [41, 50, 56]. Neither in 
the present study nor in studies by other investigators SPECT/CT 
did miss a sentinel node that was visualized by planar lymphoscin-
tigraphy [34]. SPECT/CT was able to accurately bring to light sites of 
skin contamination with the radiopharmaceutical.
Thanks to the combined imaging techniques of SPECT and 
CT, it was possible to distinguish nodal uptake from injection site 
activity. 3-D SPECT/CT images may identify hidden nodes due to 
a good separation between counts related to the tracer injection 
and those of a closely located hot lymph node [57]. 
In this study, nodes were accurately located to the anatomic 
sites. Accurate anatomic localization of SLN nodes preoperatively 
can aid in probe-directed surgery and may reduce operator-de-
pendant variation and time. It is reasonable to consider utilizing 
SPECT/CT in conjunction with planar imaging when feasible, 
especially in patients with negative planar imaging, in the hope 
of enhancing SLN detection and localization. If these data are 
confirmed, the routine use of SPECT in all patients may potentially 
have incremental value. 
According to our information from literature, so far anybody 
has ever evaluated the effect of age on the difference in detection 
success of SLN using planar scintigraphy and SPECT/CT. The 
effect of the age was investigated only for planar scintigraphy by 
Birdwell et al. [58] and by Brenot-Rossi et al. [59]. Both authors in-
vestigated influence of age only in women with breast cancer and 
came to opposite results. Brenot-Rossil et al. [59] analysed differ-
ent parameters, such as the number of positive LNs, presence of 
lymphovascular invasion, tumour size, tumour grade, histology, 
prior excisional biopsy, and patient age to determine whether they 
had any significant correlation with nonvisualization of SLNs in the 
axillary area. Patient age at diagnosis was stratified as < 70 or > 70 
years. An increased risk of unsuccessful axillary mapping was sta-
tistically associated with the number of positive axillary nodes. The 
age showed a statistical trend with lymphoscintigraphy failure: 
age < 70 years old versus >70 years old (P < 0.096, Fisher exact 
test) — patient age showed no relation to unsuccessful lymphoscin-
tigraphy. Birdwell et al. [58] compared patients with visualized and 
nonvisualized SLNs for age, tumour site, size, and histologic find-
ings, injection guidance method, diagnostic biopsy type, interval 
between biopsy and lymphoscintigraphy, intraoperative identifica-
tion method, and surgical identification rate. They proved different 
finding than Brenot-Rossi et al. [59] — there was a statistically 
significant difference between groups, with an age range of 29–79 
years (mean age, 51.8 years) in patients with visualized SLNs and of 
40–81 years (mean age, 60.2 years) in patients with nonvisualized 
SLNs. Patients with nonvisualized SLNs were older than those with 
visualized SLNs and patients with and those without visualization 
differed in age. This is similar to experience of Ng et al. [60], who 
reported an increase in failure to identify SLNs in women older 
than 50 years of age.
We have found that in people with lower average age, the 
higher number of SLNs on SPECT/CT than on planar scintigraphy 
has been detected in comparison with older patients. On the other 
hand BMI did not differ between the group of patients with higher 
number of detected SLN on SPECT/CT than on planar scintigraphy 
and the group of patients with the same number of detected SLN 
on SPECT/CT and on planar scintigraphy.
Conclusion
The addition of SPECT/CT to planar lymphoscintigraphy may 
improve the localization of preoperative draining nodes in pa-
tients with vulvar, cervical and endometrial cancers, melanomas, 
and breast cancers. It may detect SLNs nodes missed by planar 
imaging, exclude nonnodal false positive sites of uptake and ac-
curately show the exact anatomical location of visualized sentinel 
inguinal, pelvic, paraaortic, axillary, and extra-axillary nodes in 
patients with inconclusive conventional lymphoscintigrams. 
Furthermore, hybrid imaging brought additional value, espe-
cially in the group of patients with scar after extirpation of melanoma, 
where SPECT/CT visualized higher number of SLNs in 20% more 
cases than in the group of patients prior the primary surgery. Some 
factors, for example lower age, may influence imaging of SLNs with 
better results on SPECT/CT compared to planar lymphoscintigra-
phy. According to our results BMI did not influence detection re-
sults with SPECT/CT in comparison with planar lymphoscintigraphy.
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